Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

BACKGROUND: Proteasome inhibitors (PIs), including carfilzomib, potentiate the activity of selinexor, a novel, first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in preclinical models of multiple myeloma (MM). METHODS: The safety, efficacy, maximum-tolerated dose (MTD) and r...

Descripción completa

Detalles Bibliográficos
Autores principales: Gasparetto, Cristina, Schiller, Gary J., Tuchman, Sascha A., Callander, Natalie S., Baljevic, Muhamed, Lentzsch, Suzanne, Rossi, Adriana C., Kotb, Rami, White, Darrell, Bahlis, Nizar J., Chen, Christine I., Sutherland, Heather J., Madan, Sumit, LeBlanc, Richard, Sebag, Michael, Venner, Christopher P., Bensinger, William I., Biran, Noa, Ammu, Sonia, Ben-Shahar, Osnat, DeCastro, Andrew, Van Domelen, Dane, Zhou, Tianjun, Zhang, Chris, Bentur, Ohad S., Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Lipe, Brea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605887/
https://www.ncbi.nlm.nih.gov/pubmed/34802051
http://dx.doi.org/10.1038/s41416-021-01608-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8605887/
https://www.ncbi.nlm.nih.gov/pubmed/34802051
http://dx.doi.org/10.1038/s41416-021-01608-2

Ejemplares similares